NASDAQ:BIOS - BioScrip Stock Price, Price Target & More

$2.70 -0.02 (-0.74 %)

(As of 04/22/2018 12:35 PM ET)

Previous Close$2.70

Today's Range$2.68 - $2.78

52-Week Range$1.39 - $3.39

Volume218,689 shs

Average Volume650,739 shs

Market Capitalization$344.78 million

P/E Ratio-6.14

Dividend YieldN/A

Beta0.11

About BioScrip (NASDAQ:BIOS)

BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services

Sub-IndustryHealth Care Services

SectorMedical

SymbolNASDAQ:BIOS

CUSIP09069N10

Webwww.bioscrip.com

Phone720-697-5200

Debt

Debt-to-Equity Ratio-5.65%

Current Ratio1.79%

Quick Ratio1.42%

Price-To-Earnings

Trailing P/E Ratio-6.14

Forward P/E Ratio-9.64

P/E GrowthN/A

Sales & Book Value

Annual Sales$817.19 million

Price / Sales0.42

Cash FlowN/A

Price / CashN/A

Book Value($0.66) per share

Price / Book-4.09

Profitability

EPS (Most Recent Fiscal Year)($0.44)

Net Income$-64,190,000.00

Net Margins-9.45%

Return on EquityN/A

Return on Assets-9.35%

Miscellaneous

Employees2,154

Outstanding Shares127,700,000

How to Become a New Pot Stock Millionaire

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip, Inc. (NASDAQ:BIOS) announced its earnings results on Thursday, March, 8th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.07. The company had revenue of $182.50 million for the quarter, compared to analyst estimates of $171.35 million. The company's revenue was down 24.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.06) EPS. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for BioScrip.

What price target have analysts set for BIOS?

4 equities research analysts have issued 12-month price targets for BioScrip's shares. Their predictions range from $3.25 to $4.00. On average, they anticipate BioScrip's stock price to reach $3.5625 in the next twelve months. View Analyst Ratings for BioScrip.

Who are some of BioScrip's key competitors?

Some companies that are related to BioScrip include Rocket Pharmaceuticals (RCKT), Omeros (OMER), Triple-S Management (GTS), Anika Therapeutics (ANIK), New England Nuclear (LNTH), AMAG Pharmaceuticals (AMAG), RadNet (RDNT), Novavax (NVAX), Endocyte (ECYT), Hanger (HNGR), Mesa Laboratories (MLAB), Jounce Therapeutics (JNCE), Tactile Systems Technology (TCMD), Lannett (LCI), Addus HomeCare (ADUS), Reata Pharmaceuticals (RETA), Dicerna Pharmaceuticals (DRNA) and Heska (HSKA).

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:

Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)
Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
Ms. Harriet Booker, Sr. VP & COO (Age 51)
Mr. Alex Schott, Sr. VP of Strategic Operations & Interim Chief Accounting Officer (Age 48)
Ms. Jody Kepler, Sr. VP, Chief Compliance Officer & Privacy Officer (Age 48)

Has BioScrip been receiving favorable news coverage?

Media headlines about BIOS stock have been trending somewhat negative on Sunday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BioScrip earned a coverage optimism score of -0.02 on Accern's scale. They also assigned headlines about the company an impact score of 46.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are BioScrip's major shareholders?

BioScrip's stock is owned by a variety of of retail and institutional investors. Top institutional investors include ARDSLEY ADVISORY PARTNERS (0.07%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $2.70.

How big of a company is BioScrip?

BioScrip has a market capitalization of $344.78 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 950, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]

MarketBeat Community Rating for BioScrip (BIOS)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		196 (Vote Outperform)
Underperform Votes:		136 (Vote Underperform)
Total Votes:		332

MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

BioScrip (NASDAQ:BIOS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for BioScrip in the last 12 months. Their average twelve-month price target is $3.5625, suggesting that the stock has a possible upside of 31.94%. The high price target for BIOS is $4.00 and the low price target for BIOS is $3.25. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$3.5625	$3.5625	$3.8333	$3.9375
Price Target Upside:	31.94% upside	37.28% upside	44.65% upside	36.25% upside

BioScrip (NASDAQ:BIOS) Consensus Price Target History

Price Target History for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/8/2018	SunTrust Banks	Reiterated Rating	Buy	$3.25	Medium
3/8/2018	Craig Hallum	Reiterated Rating	Buy	$3.50	Medium
8/10/2017	Jefferies Group	Reiterated Rating	Buy	$3.00 -> $4.00	High
6/26/2017	Barrington Research	Boost Price Target	Outperform	$3.50	High
1/3/2017	Lake Street Capital	Initiated Coverage	Buy	$4.50	N/A

(Data available from 4/22/2016 forward)

BioScrip (NASDAQ:BIOS) Earnings History and Estimates Chart

Earnings by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.19)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.10)	($0.06)	($0.08)
Q2 2018	2	($0.07)	($0.05)	($0.06)
Q3 2018	2	($0.06)	($0.03)	($0.05)
Q4 2018	2	($0.01)	$0.00	($0.01)
Q1 2019	1	($0.04)	($0.04)	($0.04)
Q2 2019	1	($0.03)	($0.03)	($0.03)
Q3 2019	1	($0.02)	($0.02)	($0.02)

BioScrip (NASDAQ BIOS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		($0.10)					N/A
3/8/2018	Q4 2017	($0.08)	($0.15)	$171.35 million	$182.50 million	View	Listen
11/2/2017	Q3 2017	($0.10)	($0.12)	$202.91 million	$198.70 million	View	N/A
8/8/2017	Q2 2017	($0.10)	($0.11)	$220.05 million	$218.11 million	View	Listen
5/4/2017	Q1 2017	($0.12)	($0.16)	$230.23 million	$217.80 million	View	Listen
3/3/2017	Q4 2016	($0.08)	($0.08)	$236.67 million	$240.10 million	View	Listen
11/7/2016	Q3	($0.05)	($0.12)	$223.26 million	$224.50 million	View	Listen
8/8/2016	Q216	($0.09)	($0.08)	$229.58 million	$232.50 million	View	Listen
5/5/2016	Q1	($0.12)	($0.17)	$232.38 million	$238.50 million	View	Listen
3/2/2016	Q4	($0.08)	($0.13)	$238.30 million	$243.75 million	View	Listen
11/4/2015	Q315	($0.10)	($0.19)	$229.89 million	$247.20 million	View	Listen
8/10/2015	Q215	($0.11)	($0.02)	$269.38 million	$262.40 million	View	Listen
5/7/2015	Q115	($0.08)	($0.19)	$259.60 million	$261.70 million	View	Listen
3/2/2015	Q414	($0.02)	($0.72)	$259.62 million	$253.70 million	View	Listen
11/5/2014	Q314	$0.02	($0.45)	$240.08 million	$244.00 million	View	Listen
8/6/2014	Q214	($0.05)	($0.10)	$233.70 million	$247.10 million	View	Listen
5/8/2014	Q114	($0.04)	($0.17)	$222.65 million	$239.60 million	View	Listen
2/26/2014	Q413	$0.02	$0.02	$237.58 million	$243.50 million	View	Listen
11/6/2013	Q3 2013	$0.01	$0.02	$205.09 million	$208.88 million	View	N/A
8/7/2013	Q2 2013	$0.04	$0.13	$206.47 million	$190.73 million	View	Listen
5/8/2013	Q1 2013	$0.02	$0.04	$189.36 million	$199.07 million	View	Listen
3/11/2013	Q4 2012	$0.01	$0.04	$173.87 million	$180.70 million	View	Listen
11/7/2012	Q312	($0.01)	($0.01)	$159.86 million	$170.36 million	View	N/A
8/8/2012		($0.01)	($0.07)			View	N/A
5/9/2012		($0.01)	($0.05)			View	N/A
3/9/2012		$0.09	$0.12			View	N/A
11/8/2011		$0.09	$0.10			View	N/A
8/8/2011		$0.08	$0.10			View	N/A
5/3/2011		($0.01)	$0.05			View	N/A
3/11/2011		$0.04	($1.25)			View	N/A
11/2/2010	Q3 2010	$0.09	$0.05			View	N/A
7/30/2010	Q2 2010	$0.09	$0.07			View	N/A
4/30/2010	Q1 2010	$0.07	($0.01)			View	N/A
2/26/2010	Q4 2009	$0.10	$0.03			View	N/A
10/30/2009	Q3 2009	$0.10	$0.14			View	N/A
7/30/2009	Q2 2009	$0.06	$0.11			View	N/A
4/30/2009	Q1 2009	$0.04	$0.08			View	N/A
3/3/2009	Q4 2008	$0.05	$0.09			View	N/A
11/4/2008	Q3 2008	$0.05	$0.06			View	N/A
7/31/2008	Q2 2008	$0.03	$0.04			View	N/A
5/2/2008	Q1 2008	$0.05	($0.01)			View	N/A
3/4/2008	Q4 2007	$0.04	$0.06			View	N/A

(Earnings results data provided by Zacks Investment Research)

BioScrip (NASDAQ:BIOS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

BioScrip (NASDAQ BIOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 84.29%

Insider Trading History for BioScrip (NASDAQ:BIOS)

Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ BIOS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/9/2017	Daniel E Greenleaf	CEO	Buy	15,000	$2.03	$30,450.00	31,000
11/9/2017	Stephen Deitsch	CFO	Buy	10,000	$2.03	$20,300.00	10,000
9/15/2017	Michael G Bronfein	Director	Sell	27,000	$2.69	$72,630.00	129,669
9/7/2017	Coliseum Capital Management, L	Director	Sell	2,846,941	$2.93	$8,341,537.13
8/17/2017	Coliseum Capital Management, L	Director	Sell	886,478	$3.08	$2,730,352.24
11/11/2016	Jeffrey M Kreger	CFO	Buy	10,000	$1.32	$13,200.00	22,628
11/10/2016	Daniel E Greenleaf	CEO	Buy	16,000	$1.30	$20,800.00	16,000
11/10/2016	R Carter Pate	Director	Buy	20,000	$1.30	$26,000.00	84,000
6/22/2016	Coliseum Capital Management, L	Director	Buy	4,200,000	$2.00	$8,400,000.00
6/17/2016	David W Golding	Director	Buy	12,500	$2.48	$31,000.00	42,500
8/24/2015	Coliseum Capital Management, L	Director	Buy	789,503	$1.88	$1,484,265.64
8/21/2015	Coliseum Capital Management, L	Director	Buy	632,907	$1.81	$1,145,561.67
8/18/2015	David W Golding	Director	Buy	20,000	$1.54	$30,800.00	30,000
3/16/2015	Richard M Smith	CEO	Buy	5,000	$4.27	$21,350.00
3/12/2015	Yon Jorden	Director	Buy	5,000	$3.47	$17,350.00
6/16/2014	Myron Z Holubiak	Director	Sell	5,000	$7.94	$39,700.00
5/14/2014	Yon Jorden	Director	Buy	5,000	$7.21	$36,050.00	15,000
8/30/2013	Daniel Colucci	VP	Sell	18,500	$12.40	$229,400.00	2,580
8/28/2013	David Hubers	Director	Sell	11,200	$12.23	$136,976.00	71,360
8/28/2013	Patricia Bogusz	VP	Sell	39,687	$11.94	$473,862.78	5,088
8/19/2013	Kohlberg Management V, Llc	Insider	Sell	6,895,873	$13.00	$89,646,349.00
7/19/2013	Myron Z Holubiak	Director	Sell	31,200	$16.34	$509,808.00
11/13/2012	Stuart A Samuels	Director	Sell	11,200	$9.66	$108,192.00

(Data available from 1/1/2013 forward)

BioScrip (NASDAQ BIOS) News Headlines

Source:

Date	Headline
	BioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $170.23 Million www.americanbankingnews.com - April 21 at 2:34 AM
	Head to Head Survey: BioScrip (BIOS) & Amedisys Home Health and Hospice Care (AMED) www.americanbankingnews.com - April 20 at 9:22 PM
	-$0.11 Earnings Per Share Expected for BioScrip, Inc. (BIOS) This Quarter www.americanbankingnews.com - April 19 at 5:20 PM
	Analyzing Chemed (CHE) & BioScrip (BIOS) www.americanbankingnews.com - April 19 at 1:23 AM
	Pre-Market Technical Scan on Healthcare Equities -- Heron Therapeutics, Immune Pharma, Johnson & Johnson, and ... www.prnewswire.com - April 18 at 8:11 AM
	BioScrip (BIOS) Rating Lowered to Buy at BidaskClub www.americanbankingnews.com - April 14 at 6:22 PM
	BioScrip (BIOS) Cut to Sell at ValuEngine www.americanbankingnews.com - April 14 at 2:30 PM
	BioScrip Inc’s (NASDAQ:BIOS) Earnings Dropped -62.14%, Did Its Industry Show Weakness Too? finance.yahoo.com - April 11 at 8:23 AM
	BioScrip (BIOS) Lifted to "Buy" at SunTrust Banks www.americanbankingnews.com - April 11 at 12:11 AM
	BioScrip (BIOS) Raised to Hold at ValuEngine www.americanbankingnews.com - April 10 at 5:02 PM
	Reviewing BioScrip (BIOS) and Civitas Solutions (CIVI) www.americanbankingnews.com - April 9 at 11:19 PM
	Why Is BioScrip (BIOS) Down 5.6% Since its Last Earnings Report? finance.yahoo.com - April 9 at 8:13 AM
	Analyzing BioScrip (BIOS) and Amedisys Home Health and Hospice Care (AMED) www.americanbankingnews.com - April 8 at 5:06 PM
	BioScrip Inc (BIOS) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - April 8 at 3:36 AM
	Blog Exposure - Addus Homecare Completes Acquisition of Arcadia Home Care & Staffing for $18.5 Million finance.yahoo.com - April 4 at 8:14 AM
	BioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $170.23 Million www.americanbankingnews.com - April 4 at 2:30 AM
	Analysts Anticipate BioScrip Inc (BIOS) Will Post Earnings of -$0.11 Per Share www.americanbankingnews.com - April 2 at 7:12 PM
	BioScrip (BIOS) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - April 1 at 12:08 AM
	BioScrip (BIOS) Upgraded to "Buy" by BidaskClub www.americanbankingnews.com - March 30 at 6:14 PM
	BioScrip Timely Files Annual Form 10-K, Concludes Accounting Review and Provides Update on Immaterial Financial Statement Corrections finance.yahoo.com - March 26 at 8:16 AM
	Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc ... - PR Newswire (press release) www.prnewswire.com - March 21 at 8:41 AM
	New Research Coverage Highlights Real Goods Solar, LivePerson, Manhattan Associates, Natus Medical, BioScrip, and FBL Financial Group -- Consolidated Revenues, Company Growth, and Expectations for 2018 finance.yahoo.com - March 21 at 8:41 AM
	What does BioScrip Inc’s (NASDAQ:BIOS) Balance Sheet Tell Us About Its Future? finance.yahoo.com - March 19 at 5:22 PM
	BioScrip's Dull 2017 Earnings a Woe, Core Business Robust finance.yahoo.com - March 16 at 6:34 PM
	Zacks: Brokerages Expect BioScrip Inc (BIOS) to Announce -$0.11 EPS www.americanbankingnews.com - March 16 at 3:52 PM
	BioScrip Provides Update on Annual Form 10-K Filing Status ... - Business Wire (press release) www.businesswire.com - March 16 at 8:13 AM
	Why BioScrip (BIOS) Could Be Positioned for a Slump - Nasdaq www.nasdaq.com - March 15 at 8:10 AM
	INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud ... - Business Wire (press release) www.businesswire.com - March 15 at 8:10 AM
	BioScrip Inc (BIOS) Given Average Recommendation of "Hold" by Analysts www.americanbankingnews.com - March 14 at 3:42 AM
	BioScrip (BIOS) Downgraded by Zacks Investment Research www.americanbankingnews.com - March 13 at 11:49 AM
	BioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise - Nasdaq www.nasdaq.com - March 13 at 8:17 AM
	BioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise www.msn.com - March 12 at 6:44 PM
	BioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise finance.yahoo.com - March 12 at 6:44 PM
	BioScrip (BIOS) Downgraded by BidaskClub www.americanbankingnews.com - March 10 at 7:10 PM
	Glancy Prongay & Murray LLP Announces Investigation on Behalf of ... - Business Wire (press release) www.businesswire.com - March 10 at 8:16 AM
	BioScrip (BIOS) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS www.americanbankingnews.com - March 9 at 10:35 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioScrip, Inc. - BIOS - PR Newswire (press release) www.prnewswire.com - March 9 at 8:13 AM
	BioScrip accounting review identifies 'internal control deficiencies' and 'material weakness' - MarketWatch www.marketwatch.com - March 9 at 8:13 AM
	BioScrip, Inc's (BIOS) CEO Daniel Greenleaf on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 9 at 8:13 AM
	Milberg Tadler Phillips Grossman LLP Announces Investigation of ... - PR Newswire (press release) www.prnewswire.com - March 9 at 8:13 AM
	Craig Hallum Reiterates Buy Rating for BioScrip (BIOS) www.americanbankingnews.com - March 8 at 8:19 PM
	BioScrip (BIOS) Receives "Buy" Rating from SunTrust Banks www.americanbankingnews.com - March 8 at 8:16 PM
	Denver medical company discovers 'potential financial statement errors' www.bizjournals.com - March 8 at 6:52 PM
	BioScrip accounting review identifies 'internal control deficiencies' and 'material weakness' finance.yahoo.com - March 8 at 6:52 PM
	BIOSCRIP INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In BioScrip Inc. To Contact The Firm finance.yahoo.com - March 8 at 6:52 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioScrip, Inc. - BIOS finance.yahoo.com - March 8 at 6:52 PM
	Milberg Tadler Phillips Grossman LLP Announces Investigation of BioScrip, Inc. finance.yahoo.com - March 8 at 6:52 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of BioScrip, Inc. finance.yahoo.com - March 8 at 6:52 PM
	BioScrip, Inc. (BIOS) Investigated By Block & Leviton LLP For Violations Of The Federal Securities Laws www.prnewswire.com - March 8 at 2:23 PM
	BioScrip Reports Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release) www.businesswire.com - March 8 at 8:16 AM

BioScrip (NASDAQ:BIOS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

BioScrip (NASDAQ:BIOS) Income Statement, Balance Sheet and Cash Flow Statement

BioScrip (NASDAQ BIOS) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff